Milost to invest up to $10 mln in cancer detector GeneNews
Toronto cancer diagnostic company GeneNews Ltd (TSX: GEN) has struck a deal to receive up to US$10 million in debt and equity funding from Milost Global, a U.S. private equity firm. Beginning with an initial equity tranche of US$500,000, GeneNews plans to use the funds raised for working capital and other priorities, including the growth strategy for its Innovative Diagnostic Laboratory clinical reference lab business in Richmond, Virginia. Founded in 1998, GeneNews' focus on diagnostics and personalized medicine also supports early detection of other chronic diseases. The company is led by Chairman and CEO James Howard-Tripp.
9 November 2017•5 mins read
